Antibiotic Resistance in Space: A Frontier of Challenges and Opportunities

As humanity pushes the boundaries of exploration, venturing beyond our planet into the
vast expanse of space, we encounter unique challenges. One of the most intriguing and
concerning issues is the phenomenon of antibiotic resistance in space. Just trace amounts
of antibiotics in a spacecraft could be enough to let bacteria evolve deadly resistance on
long space journeys.

This blog post delves into how space travel influences antibiotic resistance, the
implications for astronauts and future missions, and the innovative research being
conducted to address this critical problem.

Antibiotic Resistance: A Global Threat

Antibiotic resistance occurs when bacteria evolve mechanisms to withstand the drugs
designed to kill them. This phenomenon has become a significant public health concern
on Earth, with resistant infections leading to longer hospital stays, higher medical costs,
and increased mortality. Understanding how microgravity and other space conditions
affect antibiotic resistance is crucial as we extend our reach into space.

Microgravity and Bacterial Behaviour

Microgravity, a condition where gravity is much weaker than on Earth, has profound
effects on living organisms. Research has shown that bacteria behave differently in space,
exhibiting increased growth rates, biofilm formation, and virulence. These changes can
influence how bacteria respond to antibiotics, potentially accelerating the development of
resistance.

Studies have indicated that spaceflight can impair the human immune system,
heightening the risk of infection for crew members on the space station. The potential
presence of antibiotic-resistant bacteria further exacerbates this risk. By monitoring and
characterising the type and frequency of these resistant organisms and understanding their
evolution in microgravity, researchers can gain valuable insights to mitigate this threat.
Additionally, on-orbit sequencing used in this research could lead to the development of
point-of-care diagnostic capabilities for future missions.

Studies conducted on the International Space Station (ISS) have provided valuable
insights. For instance, certain bacteria, such as Staphylococcus aureus and Escherichia
coli, have shown increased resistance to antibiotics when exposed to microgravity. These
findings suggest that space conditions may exacerbate the antibiotic resistance crisis,
posing a threat to the health and safety of astronauts on long-duration missions.

The Space Station as a Laboratory

The ISS serves as a unique laboratory for studying antibiotic resistance. Experiments
conducted on the station help scientists understand how bacteria adapt to the space
environment and how these adaptations affect their susceptibility to antibiotics. By
comparing bacterial behaviour in microgravity and on Earth, researchers can identify
specific genetic and physiological changes that contribute to resistance. One notable
experiment is NASA’s Microbial Tracking-2, which monitors the types of bacteria
present on the ISS, their genetic mutations, and their resistance patterns. The results of
such experiments are critical for developing strategies to mitigate the risks of
antibiotic-resistant infections in space.

Over the past two decades, the ISS has hosted nearly 300 astronauts. While astronauts
typically travel light, they unintentionally bring their microbes with them to space. This
has led to the development of a unique microbial population on the space station. In
2019, researchers conducted the first extensive survey of bacteria and fungi on board the
ISS and discovered a diverse array of microorganisms living among the astronauts. The
bacteria on the ISS thrive in conditions different from those on Earth, influenced by
factors such as ventilation, humidity, air pressure, and the number of astronauts on board.
The extreme space environment also exposes these bacteria to microgravity, radiation,
and elevated levels of carbon dioxide, forcing the microorganisms to adapt for survival.

The researchers focused on Enterobacter bugandensis, isolating 13 strains of this
bacterial species from the ISS for analysis. E. bugandensis, which is associated with the
human gastrointestinal tract, is known for its high adaptability and ability to exploit
unusual conditions to infect a host. This bacterium has been linked to severe clinical
infections, including neonatal sepsis, a blood infection found in infants younger than 90
days.

Implications for Astronaut Health

Astronauts are at a heightened risk of infections due to the closed environment of
spacecraft, where microbes can easily spread. The potential for antibiotic-resistant
infections is a significant concern, as it could compromise mission success and the health
of the crew. In the confined space of a spacecraft, where medical resources are limited,
preventing and managing infections is paramount.

Enterococci are gram-positive bacteria that originated when the ancestors of modern
animals transitioned from ocean to land, bringing their gut flora with them. Enterococcus
faecalis (EF) and Enterococcus faecium are common human commensals that can harbour
multidrug resistance and have been previously isolated on the International Space Station.
Due to their evolutionary origins, Enterococci exhibit remarkable stress resistance both
within and outside their human hosts. Their antibiotic resistance, combined with their
tolerance to desiccation, starvation, and disinfection, makes some EF strains potent
pathogens in built environments like hospitals, posing a potential risk to crew health
during space missions.

NASA’s EcAMSat mission, launched from the International Space Station, aimed to
study how E. coli bacteria respond to antibiotics in microgravity. The experiment, which
ran from November 24 to November 30, 2017, successfully investigated antibiotic
resistance, with preliminary results indicating bacterial growth in space. By comparing
these findings with ground-based studies, scientists hope to understand how microgravity
affects bacterial resistance and improve infection treatments for astronauts. This research
not only supports safer space missions but also offers insights into enhancing antibiotic
effectiveness on Earth. EcAMSat’s technology may also contribute to future life-detection
missions on other celestial bodies.

Innovative Research and Solutions

To address the challenge of antibiotic resistance in space, scientists are exploring various
innovative solutions:

Phage Therapy: Bacteriophages, viruses that infect and kill bacteria, are being
studied as an alternative to antibiotics. Phage therapy could be an effective tool
against antibiotic-resistant bacteria in space.
Genomic Approaches: Advanced genomic techniques are being used to study
bacterial mutations and resistance mechanisms. This knowledge can guide the
development of targeted therapies and preventive measures.
Antimicrobial Surfaces: Developing surfaces coated with antimicrobial agents
that can kill or inhibit bacterial growth is another area of research. Such surfaces
could help reduce the spread of bacteria in spacecraft.
Enhanced Monitoring Systems: Implementing robust microbial monitoring
systems on spacecraft to detect and respond to bacterial threats promptly is crucial
for maintaining astronaut health.

Future Missions and Beyond

As we prepare for longer missions to the Moon, Mars, and beyond, addressing antibiotic
resistance becomes even more critical. Understanding how space conditions affect
bacterial behaviour and resistance patterns will help ensure the safety and success of these
missions. Collaboration between space agencies, researchers, and medical professionals
is essential to develop effective strategies for preventing and managing infections in
space.

Antibiotic resistance in space is a frontier of challenges and opportunities. By leveraging
the unique environment of space as a laboratory, we can gain valuable insights into
bacterial behaviour and resistance mechanisms. This knowledge will not only protect the
health of astronauts but also contribute to the broader fight against antibiotic resistance
on Earth. As we continue to explore the cosmos, ensuring the safety and well-being of
our astronauts remains a top priority, and addressing antibiotic resistance is a crucial part
of this mission.